ERF.PA Eurofins Scientific EURONEXT €71.24 27 Jan 2026: earnings preview
ERF.PA stock closed at €71.24 on EURONEXT on 27 Jan 2026, ahead of Eurofins Scientific SE’s scheduled earnings release. Market closed and volume ended at 319,959 shares, with a day range of €70.46–€71.38. Investors will watch revenue growth, margin trends and guidance after the firm reported last twelve months revenue near €7.14B. This earnings spotlight focuses on what the results must show for the stock to keep its recent momentum
ERF.PA stock: recent price and trading context
Eurofins Scientific SE (ERF.PA) traded at €71.24 with a 1-day change of +0.52 and a 1-year gain of 43.21%. The 50-day average is €62.82 and the 200-day average is €61.39. Market cap stands at €12.61B. Trading volume of 319,959 versus an average of 275,324 shows steady investor interest in the Healthcare diagnostics peer group
ERF.PA stock: what to expect from the earnings report
Eurofins will report after the close on 29 Jan 2026 and the market will focus on organic revenue, margin progression and biopharma contract wins. The company disclosed FY 2024 revenue of €6.95B and H1 2025 revenue growth of 12.54%. Management commentary on pricing, lab utilisation and M&A integration will directly affect short-term guidance and the stock reaction
ERF.PA stock: valuation and financial ratios
ERF.PA shows an EPS of €2.27 and a current PE of 31.22. Key ratios include a price-to-sales of 2.36, price-to-book of 3.25, and free cash flow yield near 4.97%. Net debt to EBITDA reads 3.07, and interest coverage is 5.29. These figures highlight a premium valuation versus some healthcare peers while showing leverage that investors will monitor after earnings
Meyka AI rating and technical signals for ERF.PA stock
Meyka AI rates ERF.PA with a score out of 100: 70.23 (Grade B+, Suggestion: BUY). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Technical indicators show an RSI of 83.75 (overbought) and ADX 37.51 (strong trend). Traders should treat short-term momentum as strong but stretched
ERF.PA stock: risks, catalysts and sector context
Key risks include margin pressure from input costs, slower-than-expected lab utilisation, and large acquisitions that increase net debt. Catalysts are stronger biopharma contracts, margin expansion, and any upward guidance. The Healthcare sector average PE is 34.73, so Eurofins sits close to sector multiples. Macro sensitive flows into healthcare and diagnostics demand trends will influence ERF.PA performance
ERF.PA stock: analyst outlook and price targets
Consensus price targets are sparse, but model-based forecasts show short-term upside. Meyka AI’s monthly forecast is €75.81 and the quarterly forecast is €72.03. Independent data show revenue momentum with H1 2025 growth of 12.54%. We present realistic price targets: a conservative target of €68.00, a base case of €76.00, and an upside target of €85.00 based on margin recovery and successful M&A
Final Thoughts
Earnings on 29 Jan 2026 will set the near-term direction for ERF.PA stock. The company enters the report with €71.24 current price, a premium PE of 31.22, and strong revenue momentum with LTM revenue near €7.14B. Meyka AI’s forecast model projects a monthly target of €75.81, implying about +6.41% upside from today’s close, while the one-year model suggests €65.28, implying -8.37% downside. Investors should weigh growth and cash flow strength against leverage. Watch management guidance on organic growth and capital allocation. Meyka AI provides this as AI-powered market analysis; forecasts are model-based projections and not guarantees
FAQs
When will Eurofins (ERF.PA) report earnings
Eurofins Scientific SE is scheduled to announce earnings after market close on 29 Jan 2026. Expect commentary on organic revenue, margins and guidance that can move ERF.PA stock
What are the key numbers to watch in the ERF.PA report
Focus on revenue growth, adjusted EBIT margin, organic growth split by business line and any update to net debt. Also watch guidance and cash conversion metrics that affect ERF.PA stock valuation
How does Meyka AI view ERF.PA stock right now
Meyka AI gives ERF.PA a 70.23 score (Grade B+, Suggestion: BUY). This reflects solid growth, premium valuation and leverage that requires monitoring. Ratings are informational and not financial advice
What upside or downside do forecasts show for ERF.PA stock
Meyka AI’s monthly forecast of €75.81 implies roughly +6.41% upside versus current €71.24. The one-year model at €65.28 implies about -8.37% downside. Forecasts are model projections, not guarantees
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
